‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

(By Elizabeth Cooney for STAT)

Their phones are ringing off the hook and their email inboxes are filling up with questions without answers.

Doctors who care for patients diagnosed with Alzheimer’s disease — or people worried that they might be — are feeling the brunt of last week’s decision by the Food and Drug Administration to grant conditional approval to the first new Alzheimer’s drug in 18 years. That approval is broad, making no distinction between the mild, moderate, and advanced stages of the memory-robbing disease and setting no requirements for its diagnosis. Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org